The treatment, called Aucatzyl, has been granted marketing approval for the treatment of adult patients with relapsed or refractory B-cell precursor ALL, the London biopharmaceutical company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback